|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | C07D 471/04 | |
| A61K 31/4188 | |||
| A61P 35/00 | |||
| A61P 29/00 | |||
| A61P 11/06 |
| (11) | Patento numeris | 2292617 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 10175369.7 |
| Europos patento paraiškos padavimo data | 2006-05-18 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-03-09 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2012-07-11 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 0510390 | 2005-05-20 | GB |
| (72) |
Garcia-Echeverria, Carlos, CH
Stauffer, Frédéric, CH
Furet, Pascal, FR
|
| (73) |
Novartis AG,
Lichtstrasse 35, 4056 Basel,
CH
|
| (54) | 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors |
| 1,3-dihydro-imidazo[4,5-c]quinolin-2-ones as lipid kinase and/or pi3 kinase inhibitors |